Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Rapid communication

Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia

Authors: Yong Zou, Xudong Ma, Yiqun Huang, Lingling Hong, Jen-wei Chiao

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

Background

We have previously studied the histone acetylation in primary human leukemia cells. However, histone H3 methylation in these cells has not been characterized.

Methods

This study examined the methylation status at histone H3 lysine 4 (H3K4) and histone H3 lysine 9 (H3K9) in primary acute leukemia cells obtained from patients and compared with those in the non-leukemia and healthy cells. We further characterized the effect of phenylhexyl isothiocyanate (PHI), Trichostatin A (TSA), and 5-aza-2’-deoxycytidine (5-Aza) on the cells.

Results

We found that methylation of histone H3K4 was virtually undetectable, while methylation at H3K9 was significantly higher in primary human leukemia cells. The histone H3K9 hypermethylation and histone H3K4 hypomethylation were observed in both myeloid and lymphoid leukemia cells. PHI was found to be able to normalize the methylation level in the primary leukemia cells. We further showed that PHI was able to enhance the methyltransferase activity of H3K4 and decrease the activity of H3K9 methyltransferase. 5-Aza had similar effect on H3K4, but minimal effect on H3K9, whereas TSA had no effect on H3K4 and H3K9 methyltransferases.

Conclusions

This study revealed opposite methylation level of H3K4 and H3K9 in primary human leukemia cells and demonstrated for the first time that PHI has different effects on the methyltransferases for H3K4 and H3K9.
Appendix
Available only for authorised users
Literature
1.
2.
Strahl BD, Allis CD: The language of covalent histone modifications. Nature. 2000, 403 (6765): 41-45.CrossRefPubMed
3.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M: Loss of acetylation at lys 16 and trimethylation at lys 20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005, 37 (4): 391-400.CrossRefPubMed
4.
5.
6.
Schneider R, Bannister AJ, Kouzarides T: Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci. 2002, 27 (8): 396-402.CrossRefPubMed
7.
Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P, Zhang Y: PLU-1 is an H3K4 demethylase involved n transcriptional repression and breast cancer cell. Mol Cell. 2007, 25 (6): 801-812.CrossRefPubMed
8.
9.
Sanders SL, Portoso M, Mata J, Bahler J, Allshire RC, Kouzarides T: Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell. 2004, 119 (5): 603-614.CrossRefPubMed
10.
Zhang Y, Reinberg D: Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 2001, 15 (18): 2343-2360.CrossRefPubMed
11.
Boggs BA, Cheung P, Heard E, Spector DL, Chinault AC, Allis CD: Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes. Nat Genet. 2002, 30 (1): 73-76.CrossRefPubMed
12.
Noma KI, Grewal SI: Histone H3 lysine 4 methylation is mediated by Set1 and prmotes maintenance of active chromatin states in fission yeast. Proc Natl Acad Sci U S A. 2002, 4: 16438-16445.CrossRef
13.
Lachner M, Jenuwein T: The many faces of histone lysine methylation. Curr Opin Cell Biol. 2002, 14 (3): 286-298.CrossRefPubMed
14.
Klose RJ, Kauin EM, Zhang Y: JmjC-domain- containing proteins and histone demethylation. Nat Rev Genet. 2006, 7 (9): 715-727.CrossRefPubMed
15.
16.
Tan JH, Cang SD, Ma YH, Petrillo RL, Liu DL: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-PubMedCentralCrossRefPubMed
17.
Lu LL, Liu DL, Ma XD, Beklemishev A, Seiter K, Ahmed T, Chiao JW: The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep. 2006, 16 (6): 1363-1367.PubMed
18.
Ma XD, Fang YQ, Beklemisheva A, Dai W, Feng JY, Ahmed T, Liu DL, Chiao JW: Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatin to induce growth arrest in human leukemia cells. Int J Oncol. 2006, 28 (5): 1287-1293.PubMed
19.
Lu QY, Lin XH, Feng J, Zhao XM, Gallagher R, Lee MY, Chiao JW, Liu DL: Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol. 2008, 1: 6-PubMedCentralCrossRefPubMed
20.
Xiao LY, Huang YQ, Zhen RJ, Chiao JW, Liu DL, Ma XD: Deficient Histone Acetylation in Acute Leukemia and the Correction by an Isothiocyanate. Acta Haematol. 2010, 123 (2): 71-76.CrossRefPubMed
21.
Huang YQ, Ma XD, Zhen RJ, Chiao JW, Liu DL: Experimental study of PHI on methylation and acetylation in Molt-4 T cells. Zhonghua Xue Ye Xue Za Zhi. 2007, 28 (9): 612-615.PubMed
22.
Nguyen CT, Wisenberger DJ, Velicescu M, Conzales FA, Lin JC, Liang G, Jones PA: Histone H3-lysine 9 methylation is associated with aberrant gene selincing in cancer cells and is rapidly reversed by 5-aza-2’deoxycytidine. Cancer Res. 2002, 62 (22): 6456-6461.PubMed
23.
Hendzel MJ, Davie JR: Distribution of methylated histone and histone methyltransferases in chicken erythrocyte chromatin. J Biol Chem. 1989, 264 (32): 19208-19214.PubMed
24.
Annunziato AT, Eason MB, Perry CA: Relationship between methylation and acetylation of arginine-rich histone in cycling and arrested Hela cells. Biochemistry. 1995, 34 (9): 2916-2924.CrossRefPubMed
25.
Jiang SH, Ma XD, Huang YQ, Xu YL, Zheng RJ: Phenylhexyl isothiocyanate induces gene p15 demethylation by down-regulating DNA methyltransferases in molt-4 cells. Yao Xue Xue Bao. 2009, 44 (4): 350-354.PubMed
26.
Nimura K, Ura K, Kaneda Y: Histone methyltransferases: regulation of transcription and contribution to human disease. J Mol Med. 2010, 88 (12): 1213-1220.CrossRefPubMed
27.
Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E: The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci U S A. 1998, 95 (8): 4152-4157.PubMedCentralCrossRefPubMed
28.
Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y: SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004, 6 (8): 731-740.CrossRefPubMed
29.
Tachibana M, Sugimoto K, Fukushima T, Shinkai Y: Set domain-containing protein, G9a, is a novel lysinepreferring mammalian histone methyltran-sferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem. 2001, 276 (27): 25309-25317.CrossRefPubMed
30.
Peters AH, O' Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S, Doyle M, Sibilia M, Jenuwein T: Loss of the Suv39h histone methyltransferases impairsmammalian heterochromatin and genome stability. Cell. 2001, 107 (3)): 323-337.CrossRefPubMed
31.
Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ: SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 2002, 16 (8): 919-932.PubMedCentralCrossRefPubMed
32.
Yang L, Xia L, Wu DY, Wang H, Chansky HA, Schubach WH, Hickstein DD, Zhang Y: Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene. 2002, 21 (1): 148-152.CrossRefPubMed
33.
Christman JK: 5-azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002, 21 (35): 5483-5495.CrossRefPubMed
34.
Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics: inhibitors of MDM2. ALK and PARP. J Hematol Oncol. 2011, 4: 16-CrossRefPubMed
35.
36.
37.
38.
Metadata
Title
Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia
Authors
Yong Zou
Xudong Ma
Yiqun Huang
Lingling Hong
Jen-wei Chiao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-36

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue

Letter to the Editor

SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia

Letter to the Editor

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

Review

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

Research

Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

Rapid communication

Altered expression of the TCR signaling related genes CD3 and FcεRIγ in patients with aplastic anemia

Review

Targeted drug delivery for cancer therapy: the other side of antibodies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits